Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence Among Black Men Who Have Sex With Men (BMSM) in Three U.S. Cities
Médicament Data
Données recueillies dès le début de l'étude - ProspectiveInfections transmises par le sang+13
+ Maladies génito-urinaires
+ Maladies Génitales
Cohorte
Suivi d'un groupe de personnes dans le temps pour mieux comprendre les causes et l'évolution d'une maladie.Résumé
Date de début de l'étude : 15 août 2013
Date à laquelle le premier participant a commencé l'étude.An open label demonstration study with PrEP and Client Centered Care Coordination (C4) to assess the initiation, acceptability, safety, and feasibility of PrEP for Black MSM (BMSM) in three US Cities. A subset of participants will also be recruited to participate in qualitative interviews about facilitators and barriers regarding PrEP. The study will recruit HIV-uninfected BMSM at risk for HIV infection in three US Cities. Enrollment will include those aged 18 and over with an effort to recruit an equal number of BMSM under age 25 and over age 25 with a total of 225 participants (75 per site).
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.226 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Cohorte
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Homme
Le sexe biologique des participants éligibles à s'inscrire.À partir de 18 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria: BMSM who meet all of the following criteria are eligible for inclusion in this study: 18 years of age or older No prior HIV diagnosis (self-report) Male at birth High risk for acquiring HIV infection including any one of the following in the previous 6 months: Unprotected sex during receptive or insertive anal intercourse with a male partner Any protected or unprotected: i. Receptive or insertive anal intercourse with more than three male sex partners ii. Exchange of money, gifts, shelter or drugs for receptive or insertive anal sex with a male partner iii. Receptive or insertive anal sex while under the influence of drugs or alcohol (i.e., high or drunk within two hours of the sex act) according to self-report" STI diagnosis (i.e., syphilis, gonorrhea and chlamydia) by self-report Willing to provide locator information in accordance with the Study Specific Procedures (SSP) Manual Urine dipstick negative or trace for protein and glucose Hemoglobin > 11 g/dL, absolute neutrophil count > 750 cells/mm3, and platelet count ≥ 100,000/mm3 Serum creatinine < upper limit of normal (ULN) and calculated creatinine clearance of at least 60 mL/min by the Cockcroft-Gault formula where: o eCcr in mL/min = [(140 - age in years) x (actual body weight in kg)] / (72 x serum creatinine in mg/dL) Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) < 3 times the upper limit of normal (ULN) Total bilirubin < 2.5 ULN Hepatitis B surface antigen (HBsAg) negative Exclusion Criteria: BMSM who meet any of the following criteria will be excluded from this study: Any reactive or positive HIV test at Screening, even if subsequent testing indicates that the person is HIV-uninfected Transgender Active or chronic hepatitis B infection (as evidenced by HBsAg, HbsAb, and HbcAb testing) Planning to move out of the area or to travel for more than 3 months during the study follow-up period Unwilling to adhere to study procedures Current participation in any research study via self-report (however, strictly non-HIV centered observational studies are not exclusionary) Previous participation in an HIV vaccine study is exclusionary unless documented evidence of enrollment into a placebo arm Use of ARV drugs (PrEP or PEP) in the last 60 days Prior history of a gastrectomy, colostomy, ileostomy, or any other procedure altering the gastrointestinal tract or drug absorption (provided by self-report, or obtained from medical history or records) Receipt of prohibited medications: interleukin therapy, medications with significant nephrotoxic potential (including but not limited to amphotericin B, aminoglycosides, cidofovir, foscarnet and systemic chemotherapy), and medications that may inhibit or compete for elimination via active renal tubular secretion (including but not limited to probenecid) - (provided by self-report, or obtained from medical history or medical records) Any condition, that in the opinion of study staff, would make participation in the study unsafe, or interfere with achieving the study objective
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.Un seul groupe d'intervention est désigné dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Objectifs de l'étude
Objectifs principaux
Objectifs secondaires
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 3 sites
George Washington University CRS
Washington D.C., United StatesUNC CRS
Chapel Hill, United States